CSBio CSBio

X
[{"orgOrder":0,"company":"Dexa Medica","sponsor":"Debiopharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Debiopharm and Dexa Medica Launch Triptorelin Collaboration to Bring New Hope to Women With Endometriosis","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"INDONESIA","productType":"Large molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Dexa Medica"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Dexa Medica’s nation-wide launch and distribution of triptorelin, as Debiopharm’s exclusive Indonesian licensee, will help patients in the region gain access to the pain-relieving benefits of hormone suppression with Pamorelin®.

            Lead Product(s): Triptorelin Pamoate

            Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Pamorelin

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Debiopharm

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration October 07, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY